PUBLISHER: TechSci Research | PRODUCT CODE: 1698023
PUBLISHER: TechSci Research | PRODUCT CODE: 1698023
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Neuralgia Treatment Market was valued at USD 1.21 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.84% through 2030. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions.The global neuralgia treatment market is driven by factors such as the rising prevalence of neurological disorders, increasing geriatric population, advancements in drug development, growing awareness about pain management, enhanced healthcare access, and the rising demand for effective treatments for chronic pain conditions like trigeminal neuralgia and postherpetic neuralgia. For instance, in June 2024, the Australian Government committed USD 19.6 million from the Medical Research Future Fund to improve primary healthcare, emphasizing chronic pain and multidisciplinary care. USD 8.8 million will support chronic pain initiatives, focusing on rural communities and adapting programs to reduce disability, enhancing healthcare access and outcomes.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 1.21 Billion |
Market Size 2030 | USD 2.00 Billion |
CAGR 2025-2030 | 8.84% |
Fastest Growing Segment | Online Pharmacies |
Largest Market | North America |
Key Market Drivers
Rising Prevalence of Neuralgia-Related Conditions
Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry. According to a 2024 Multiple Sclerosis (MS) Society study, over 150,000 people in the UK are living with multiple sclerosis (MS), with the increase attributed to improved diagnoses and longer life expectancies rather than a higher risk. The regional prevalence is: around 123,000 in England (1 in 450), 6,100 in Wales (1 in 500), 5,300 in Northern Ireland (1 in 350), and 17,400 in Scotland (1 in 300). Annually, more than 7,100 new cases are diagnosed, which averages to about 135 weekly.
Key Market Challenges
Underdiagnosis and Misdiagnosis
A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.
Key Market Trends
Advanced Diagnostic Tools
Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.
In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.
Global Neuralgia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: